Market Overview:
The global ritonavir market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of HIV/AIDS, rising demand for generic drugs and increasing number of clinical trials for ritonavir. Based on type, the global ritonavir market is segmented into tablets, oral solution and oral powder. The tablets segment is expected to account for the largest share in terms of revenue in 2018. This can be attributed to their high adoption rate across regions and growing demand from adult patients. Based on application, the global ritonavir market is segmented into adult and children patients. The adult patients segment accounted for majority share in 2017 and this trend is projected to continue during the forecast period owing to increase in incidence rates of HIV/AIDS globally. Geographically, North America dominates the global ritonavir market followed by Europe due with a significant contribution from countries such as U.S.
Product Definition:
A protease inhibitor used in the treatment of HIV infection. Ritonavir is also important in the development of new antiretroviral drugs because it enhances the activity of other protease inhibitors.
Tablets:
Tablets are small pieces of paper or thin films containing an amount of drug usually for oral administration. They can be used as a dosage form and may also serve other functions such as the delivery of specific drugs to certain areas of the body (site-specific drug delivery). Tablets are convenient in size and shape, which makes them easy to swallow. Furthermore, they offer controlled release allowing more precise dosing by reducing gastrointestinal irritation caused by rapid absorption in capsule or solution forms.
Oral solution:
Oral solution is a form of drug delivery route which involves the direct administration of the active pharmaceutical ingredient to the site of action. The oral dosage forms are available in various types such as syrups, tablets, solutions and suspensions. Oral solutions are usually easy to administer and they offer several advantages over other dosage forms like injections or pills; this factor makes it more preferred for drugs with low therapeutic value or low solubility in body fluids like blood or milk.
Application Insights:
The global ritonavir market is categorized based on the application as adult and children. In 2017, the adult segment held a larger share of over 70% in terms of revenue. This is attributed to the high prevalence of HCV infection among adults which requires immediate treatment with antiviral drugs. According to WHO, around 60% to 90% of people infected with hepatitis C are estimated to beymembersof populations at high-risk for viral hepatitis due to injection drug use or sexual contact with an infected individual. Thus, increasing awareness about HCV infection and its transmission among adults is expectedto boost demand forrionavir tablets & oral solution over the forecast period.
Ritonavir powder has been approved by FDA under category X for use in pediatric patients 2 years.
Regional Analysis:
Asia Pacific dominated the global ritonavir market in 2017, with a revenue share of over 45%. The presence of key manufacturers such as Dr. Reddy's Laboratories Limited and WOCKHARDT LIMITED in the region has led to its large share. Furthermore, increasing prevalence of HIV/AIDS is also one of the major factors contributing to its large share. According to WHO, around 6 million people were diagnosed with HIV globally till 2016; however, due to lack of awareness and low testing rates it was estimated that around 3 million more people were infected till then (13). This scenario is further anticipated to get worse if immediate steps are not taken for containing this pandemic by spreading it across all countries worldwide.
Growth Factors:
- Increasing prevalence of HIV/AIDS and other viral infections: The increasing prevalence of HIV/AIDS and other viral infections is a major growth driver for the ritonavir market. According to the World Health Organization (WHO), there were about 36.7 million people living with HIV/AIDS in 2017, and this number is expected to increase to about 39 million by 2020. This will create a high demand for ritonavir-based therapies, thereby driving the growth of the ritonavir market.
- Rising incidence of drug-resistant viruses: The rising incidence of drug-resistant viruses is another major growth driver for the ritonavir market. Drug resistance can develop when patients do not take their medications as prescribed or when they share medication with others who have resistant strains of virus infection. This can lead to treatment failure and increased morbidity and mortality rates among patients infected with drug-resistant viruses. As a result, there is an increasing demand for novel antiviral drugs such as ritonavir that can effectively treat these infections..
Scope Of The Report
Report Attributes
Report Details
Report Title
Ritonavir Market Research Report
By Type
Tablets, Oral solution, Oral powder
By Application
Adult, Children
By Companies
AbbVie, Hikma Pharmaceuticals, Cipla, Mylan, HETERO, Aurobindo Pharma, Amneal Pharmaceuticals, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Ritonavir Market Report Segments:
The global Ritonavir market is segmented on the basis of:
Types
Tablets, Oral solution, Oral powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Hikma Pharmaceuticals
- Cipla
- Mylan
- HETERO
- Aurobindo Pharma
- Amneal Pharmaceuticals
- ...
Highlights of The Ritonavir Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets
- Oral solution
- Oral powder
- By Application:
- Adult
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ritonavir Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ritonavir is a medication used to treat HIV infection. It works by blocking the virus from entering cells and multiplying.
Some of the key players operating in the ritonavir market are AbbVie, Hikma Pharmaceuticals, Cipla, Mylan, HETERO, Aurobindo Pharma, Amneal Pharmaceuticals.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ritonavir Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ritonavir Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ritonavir Market - Supply Chain
4.5. Global Ritonavir Market Forecast
4.5.1. Ritonavir Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ritonavir Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ritonavir Market Absolute $ Opportunity
5. Global Ritonavir Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ritonavir Market Size and Volume Forecast by Type
5.3.1. Tablets
5.3.2. Oral solution
5.3.3. Oral powder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ritonavir Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ritonavir Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ritonavir Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ritonavir Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ritonavir Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ritonavir Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ritonavir Demand Share Forecast, 2019-2029
9. North America Ritonavir Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ritonavir Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ritonavir Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ritonavir Market Size and Volume Forecast by Type
9.7.1. Tablets
9.7.2. Oral solution
9.7.3. Oral powder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ritonavir Demand Share Forecast, 2019-2029
10. Latin America Ritonavir Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ritonavir Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ritonavir Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ritonavir Market Size and Volume Forecast by Type
10.7.1. Tablets
10.7.2. Oral solution
10.7.3. Oral powder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ritonavir Demand Share Forecast, 2019-2029
11. Europe Ritonavir Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ritonavir Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ritonavir Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ritonavir Market Size and Volume Forecast by Type
11.7.1. Tablets
11.7.2. Oral solution
11.7.3. Oral powder
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ritonavir Demand Share, 2019-2029
12. Asia Pacific Ritonavir Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ritonavir Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ritonavir Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ritonavir Market Size and Volume Forecast by Type
12.7.1. Tablets
12.7.2. Oral solution
12.7.3. Oral powder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ritonavir Demand Share, 2019-2029
13. Middle East & Africa Ritonavir Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ritonavir Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ritonavir Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ritonavir Market Size and Volume Forecast by Type
13.7.1. Tablets
13.7.2. Oral solution
13.7.3. Oral powder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ritonavir Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Ritonavir Market: Market Share Analysis
14.2. Ritonavir Distributors and Customers
14.3. Ritonavir Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Hikma Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cipla
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Mylan
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. HETERO
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aurobindo Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Amneal Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ...
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
